Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

NCT04352855 is registered in ClinicalTrials.gov with Semmelweis University as lead sponsor.

NCT NCT04352855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04352855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.
Lead sponsor
Semmelweis University
Phase
Observational
Overall status
Unknown status
Start date
January 18, 2018
Completion date
May 19, 2020
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotic resistant infection, ventilator associated pneumonia